| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 2034* | 2021 |
| SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses W Dejnirattisai, J Huo, D Zhou, J Zahradník, P Supasa, C Liu, ... Cell 185 (3), 467-484. e15, 2022 | 922 | 2022 |
| Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 743 | 2021 |
| Effect of noninvasive respiratory strategies on intubation or mortality among patients with acute hypoxemic respiratory failure and COVID-19: the RECOVERY-RS randomized … GD Perkins, C Ji, BA Connolly, K Couper, R Lall, JK Baillie, JM Bradley, ... Jama 327 (6), 546-558, 2022 | 316 | 2022 |
| Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre … CD Russell, CJ Fairfield, TM Drake, L Turtle, RA Seaton, DG Wootton, ... The Lancet Microbe 2 (8), e354-e365, 2021 | 296 | 2021 |
| Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study RK Gupta, EM Harrison, A Ho, AB Docherty, SR Knight, M van Smeden, ... The Lancet Respiratory Medicine 9 (4), 349-359, 2021 | 220 | 2021 |
| The coagulation and immune systems are directly linked through the activation of interleukin-1α by thrombin LC Burzynski, M Humphry, K Pyrillou, KA Wiggins, JNE Chan, N Figg, ... Immunity 50 (4), 1033-1042. e6, 2019 | 203 | 2019 |
| Effect of convalescent plasma on organ support–free days in critically ill patients with COVID-19: a randomized clinical trial H Abdelhady, M Abdelrazik, Z Abdi, D Abdo, A Abdulle, L Abel, ... Jama 326 (17), 1690-1702, 2021 | 193 | 2021 |
| Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the … CI Bloom, TM Drake, AB Docherty, BJ Lipworth, SL Johnston, ... The Lancet Respiratory Medicine 9 (7), 699-711, 2021 | 169 | 2021 |
| Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study A Fendler, STC Shepherd, L Au, KA Wilkinson, M Wu, F Byrne, M Cerrone, ... Nature cancer 2 (12), 1305-1320, 2021 | 164 | 2021 |
| A prenylated dsRNA sensor protects against severe COVID-19 A Wickenhagen, E Sugrue, S Lytras, S Kuchi, M Noerenberg, ML Turnbull, ... Science 374 (6567), eabj3624, 2021 | 151 | 2021 |
| Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study TM Drake, AM Riad, CJ Fairfield, C Egan, SR Knight, R Pius, ... The Lancet 398 (10296), 223-237, 2021 | 148 | 2021 |
| Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK AB Docherty, RH Mulholland, NI Lone, CP Cheyne, D De Angelis, ... The Lancet Respiratory Medicine 9 (7), 773-785, 2021 | 98 | 2021 |
| Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial S Florescu, D Stanciu, M Zaharia, A Kosa, D Codreanu, A Kidwai, ... Jama 329 (1), 39-51, 2023 | 88 | 2023 |
| Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study TM Drake, CJ Fairfield, R Pius, SR Knight, L Norman, M Girvan, ... The Lancet Rheumatology 3 (7), e498-e506, 2021 | 87 | 2021 |
| Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer A Fendler, STC Shepherd, L Au, M Wu, R Harvey, AM Schmitt, Z Tippu, ... The Lancet 399 (10328), 905-907, 2022 | 77 | 2022 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 399 (10325), 665-676, 2022 | 76 | 2022 |
| SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination F Liew, S Talwar, A Cross, BJ Willett, S Scott, N Logan, MK Siggins, ... EBioMedicine 87, 2023 | 72 | 2023 |
| The impact of viral mutations on recognition by SARS-CoV-2 specific T cells TI de Silva, G Liu, BB Lindsey, D Dong, SC Moore, NS Hsu, D Shah, ... Iscience 24 (11), 2021 | 63 | 2021 |
| Mesenchymal stem cells enhance NOX2-dependent reactive oxygen species production and bacterial killing in macrophages during sepsis R Rabani, A Volchuk, M Jerkic, L Ormesher, L Garces-Ramirez, J Canton, ... European Respiratory Journal 51 (4), 2018 | 63 | 2018 |
